Last reviewed · How we verify
NCT03714763
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
NA trial testing Drug treatment in Pituitary Adenoma in 50 participants. Status unknown.
30 November 2021
Quick facts
| Lead sponsor | Zhebao Wu |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 November 2018 |
| Primary completion | 30 November 2021 |
| Estimated completion | 31 January 2022 |
Drugs / interventions tested
- Drug treatment — full drug profile →
- Surgery
Conditions studied
- Pituitary Adenoma — all drugs for Pituitary Adenoma →
Sponsor
Zhebao Wu — full company profile →
Who can join
Adults 18 to 65, any sex, with Pituitary Adenoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists（DA）.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03714763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Drug treatment
Trials testing the same drug.
- NCT07037472 — Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treat · NA · recruiting
- NCT03717454 — Dopamine D2 Receptors(D2R) Imaging in Prolactinomas · NA · unknown
- NCT04451603 — LiverMultiScan Analysis of MRI Scans in HCC · completed
- NCT03651674 — Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study · NA · unknown
Other recruiting trials for Pituitary Adenoma
Currently open trials in the same condition.
- NCT04569591 — DDAVP for Pituitary Adenoma · NA · recruiting
- NCT06831461 — Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors · NA · recruiting
- NCT06973824 — A Twenty-years' Experience in Pituitary Disease. · recruiting
- NCT06679816 — Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors · Phase 4 · recruiting
- NCT06584123 — Molecular Pituitary Imaging Using 18F-FET PET · NA · recruiting
Other Zhebao Wu trials
Trials by the same sponsor.
- NCT04018963 — The Impact of Endoscopic Pituitary Surgery on Nasal Function · unknown
- NCT03717454 — Dopamine D2 Receptors(D2R) Imaging in Prolactinomas · NA · unknown
- NCT03400865 — Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03714763 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhebao Wu
- Last refreshed: 22 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03714763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing